THE PHARMACOGNOSTIC AND PHARMACOLOGICAL ASPECTS OF THE CREATING OF THE NEW SEDATIVE DRUGS BASED ON MEDICINAL PLANT RAW MATERIALS

DOI: https://doi.org/10.29296/25877313-2018-03-01
Download full text PDF
Issue: 
3
Year: 
2018

M.G. Tokareva Post-graduate Student, Department of Pharmaceutical Chemistry, Pharmacognosy and Organization of Pharmaceutical Business, Lomonosov Moscow State University; Research Scientist, Department of Pharmaceutical Technology, All-Russian Scientific Research Institute of Medicinal and Aromatic Plants (Moscow) E-mail: t-mehri@yandex.ru Y.E. Prozhogina Student, faculty of fundamental medicine, Lomonosov Moscow State University E.I. Kalenikova Dr.Sc. (Pharm.), Head of Department of Pharmaceutical chemistry, Pharmacognosy and Organization of Pharmaceutical Business, Lomonosov Moscow State University E-mail: eikaleni@fbm.msu.ru M.A. Dzhavakhyan Ph.D. (Pharm.), Associate Professor, Lomonosov Moscow State University; Head of Department of Pharm Technologies, All-Russian Institute of Medicinal and Aromatic Plants (Moscow)

In the modern world, the number of nervous disorders, caused by stress factors, such as psychologically unfavorable living conditions, environmental degradation, etc., is steadily increasing. The slightest disturbance in the work of the nervous system has a significant effect on the quality of life of a person and can cause the development of diseases of other body systems (cardiovascular, endocrine, digestive). Despite the presence of the synthetic sedatives, anxiolytics and antidepressants, herbal sedative drugs are widely used in medical practice with increased irritability, neuroses, sleep disorders and neurasthenia. The article presents some data of information and analytical analysis of literature data, including a description of medicinal plant material, the spectrum of pharmacological effects of which is promising for the development of new combined sedatives. The attention to the problem of choosing a sedative drug for the treatment of nervous system disorders is given. At the present time in the Russian pharmaceutical market among medicinal herbal preparations of sedative action a significant share is made of foreign-made products. There is a lack of domestic multicomponent sedative drugs, as well as preparations for children. One of the methods of increasing the nomenclature of these medicinal products is the development of dosage forms containing medicinal plant raw materials. The results of experimental studies of scientists from around the world presented in this article, show the high efficiency and the possibility of using of the plant resources to create effective sedative drugs.

Keywords: 
medicinal plant raw materials
herbal remedy
sedative effect

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Kessler R.C., Wang P.S. The descriptive epidemiology of commonly occurring mental disorders in the United States //Annu. Rev. Public Health. 2008;29:115−129.
  2. Mitihina I.A., Mitihin V.G., Jastrebov V.S., Limankin O.V. Psihicheskoe zdorov'e naselenija mira: epidemiologicheskij aspekt (zarubezhnye issledovanija2000−2010 gg.) // Zhurnal nevrologii i psihiatrii im.S.S. Korsakova. 2011;111.6:4−14.
  3. Mitihina I.A., Mitihin V.G., Jastrebov V.S. Limankin O.V. Psihicheskoe zdorov'e naselenija Rossijskoj Federatsii v period 1992−2010 gg. // Zhurnal nevrologii ipsihiatrii im. S.S. Korsakova. 2013. T. 113. № 9. S. 4−13.
  4. Tresserras-Gaju R., Medina-Bustos A., Mompart-Penina A. et al. Individual and population-based risk in mental health in Catalonia, Spain // Med. Clin. (Barc). 2011. № 137. P. 16−21.
  5. Wittchen H.U., Jacobi F., Rehm J. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010 // Eur. Neuropsychopharmacol. 2011. V. 21. № 9. P. 655−679.
  6. Mitihina I.A., Mitihin V.G., Jastrebov V.S. Limankin O.V. Epidemiologicheskie modeli vlijanija sotsial'no-ekonomicheskih faktorov na pokazateli psihicheskogo zdorov'ja naselenija Rossijskoj Federatsii v period 1992−2008 gg. // Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012. № 4. S. 4−10.
  7. Saxena S., Setoya Y. World Health Organization’s comprehensive mental health action plan 2013–2020 // Psychiatry and clinical neurosciences. 2014. V. 68. № 8. P. 585−586.
  8. Voznesenskaja T.G. Emotsional'nyj stress i profilaktika ego posledstvij // RMZh. 2006. T. 14. № 9. S. 694−697.
  9. Gosudarstvennaja Farmakopeja RF. XIII izdanie.
  10. Volz H.P, Murck H., Kasper S. et al. St. John’swort extract (LI 160) in somatoform disorders:results of a placebo-controlled trial // Psychopharmacology (Berl). 2002. № 164. P. 294−300.
  11. Russo E., Scicchitano F., Whalley B.J. et al. Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug–drug interactions // Phytotherapy research. 2014. V. 28. № 5. P 643−655.
  12. Sarris J., Mischoulon D. Treatments for comorbid anxiety and mood disorders // Evidence-Based Herbal and Nutritional Treatments for Anxiety in Psychiatric Disorders. Springer. Cham. 2017. P. 103−119.
  13. Ben-Eliezer D., Yechiam E. Hypericum perforatum as a cognitive enhancer in rodents: A meta-analysis // Scientific reports. 2016. P. 35700.
  14. Whiskey E., Werneke U., Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: a comprehensive clinical review // Int Clin Psychopharmacol. 2001. V. 6. № 5. P. 239−252
  15. Newby J.M., McKinnon A., Kuyken W. et al. Systematic review and meta-analysis of transdiagnostic psychological treatments for anxiety and depressive disorders in adulthood // Clinical Psychology Review. 2015. № 40. P. 91−110.
  16. Yasar S.N., Can O.D., Ozturk N. et al. Central nervous system activities of Hypericum origanifolium extract via GABAergic and opioidergic mechanisms // Phytotherapy Research. 2013. V. 27. № 6 P. 877−884.
  17. Zanoli P. Role of hyperforin in the pharmacological activities of St. John’s Wort // CNS drug reviews. 2004. V. 10. № 3. P. 203−218.
  18. Cakir A., Mavi, A., Yıldırım, A. et al. Isolation and characterization of antioxidant phenolic compounds from the aerial parts of Hypericum hyssopifolium L. by activity-guided fractionation // Journal of Ethnopharmacology. 2003. V. 87. № 1. P. 73−83.
  19. Sharma M.K., Ram V., Kush L. Molecular Pharmacology Of Antidepressive Terrestrial Natural Products (TNPs) // International Journal of Innovative Research and Development 2013. № 2. P. 6.
  20. Noldner M., Schotz K. Rutin is essential for the antidepressant
  21. activity of Hypericum perforatum extracts in the forced
  22. swimming test // Planta Medica. 2002. V. 68.№ 7 P. 577−580.
  23. Ushkalova A.V., Illarionova T.S. Effektivnost' i bezopasnost' antidepressivnyh i sedativnyh sredstv rastitel'nogo proishozhdenija // Farmateka. 2007. № 20. P. 10−14.
  24. Marrelli M., Conforti F., Toniolo C. et al. Hypericum perforatum: influences of the habitat on chemical composition, photo-induced cytotoxicity, and antiradical activity // Pharmaceutical biology. 2014. V. 52. № 7. P. 909−918.
  25. Zuzuk B.M., Kutsik R.V. Melissa lekarstvennaja (Melissa officinalis L.) Analiticheskij obzor // Provizor. 2002. № 1. C. 36−39.
  26. Bagdat R.B., Coşge B. The essential oil of lemon balm (Melissa officinalis L.), its components and using fields // J. Fac. Agric. OMU. 2006. V. 21. № 1. P. 116−121.
  27. Howes M.J.R., Perry E. The role of phytochemicals in the treatment and prevention of dementia // Drugs & aging. 2011. V. 28. № 6. P. 439−468.
  28. Wake G., Court J., Pickering A. et al. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory // J. Ethnopharmacol. 2000 № 69. P. 105−114.
  29. Encalada M.A. et al. Anti-proliferative effect of Melissa officinalis on human colon cancer cell line // Plant foods fo human nutrition. 2011. V. 66.№ 4. P. 328−334.
  30. Kennedy D.O., Little W., Scholey A.B. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm) // Psychosom Med. 2004. V. 66. № 4. P. 607−613.
  31. Yarnell E. Herbal medicine for insomnia // Alternative and Complementary Therapies. 2015. V. 21. № 4. P. 173−179.
  32. Vorob'eva O.V. Psihovegetativnyj sindrom, assotsiirovannyj s trevogoj (voprosy diagnostiki i terapii) // RMZh. 2006. V. 14. № 23. P. 1696−1699.
  33. Miaomiao Jia, Chenxin Li, Ying Zheng et al. Leonurine exerts antidepressant-like effects in the chronic mild stress-induced depression model in mice by inhibiting neuroinflammation // International Journal of Neuropsychopharmacology. 2017. V. 20. № 11.P. 886–895.
  34. Ovanesov K.B. Vlijanie tofizopama i nastojki pustyrnika na tsvetovosprijatie u molodyh ljudej // Eksperimental'naja i klinicheskaja farmakologija. 2005. V. 68. № 3. P. 56−59.
  35. Deng X.Y., Li H.Y., Chen J.J. et al. Thymol produces an antidepressant-like effect in a chronic unpredictable mild stress model of depression in mice // Behav Brain Res. 2015 № 291. P. 12−19.
  36. Ding L., Zhao F., Chen L. et al. New monoterpene glycosides from Paeonia suffruticosa andrews and their inhibition on NO production in LPS-induced RAW 264.7 cells // Bioorg. Med. Chem. Lett. 2012. № 22. P. 7243–7247.
  37. Hao G., Zhao W., Lei Y. et al. Five new bidesmoside triterpenoid saponins from Stauntonia chinensis // Magnetic Resonance in Chemistry. 2008. № 46. P. 630−637.
  38. Riaz N., Anis I., Malik A. et al. Paeonins A and B, lipoxygenase inhibiting monoterpene galactosides from Paeonia emodi // Chemical and pharmaceutical bulletin. 2003. № 5. P. 1252−254.
  39. Fu Q., Qiu L., Yuan H.M. et al. Paeonenoides D and E: two new nortriterpenoids from Paeonia lactiflora and their inhibitory activities on NO production // Helvetica Chimica Acta. 2016. № 99. P. 46−49.
  40. Guo R.B., Wang G.F., Zhao A.P. et al. Paeoniflorin protects against ischemia-induced brain damages in rats via inhibiting MAPKs/NF-κB-mediated inflammatory responses // PLoS One. 2012. V. 7. № 11:e49701.
  41. Chen C.R., Sun Y., Luo Y.J. et al. Paeoniflorin promotes nonrapid eye movement sleep via adenosine A1 receptors // Journal of Pharmacology and Experimental Therapeutics. 2016. V. 356. № 1. P. 64−73.
  42. Benke D., Barberis A., Kopp S. et al. GABAA receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts // Neuropharmacology. 2009. V. 56. № 1. P. 174−181.
  43. Morohina S.L., Musina N.Z., Aljautdin R.N. i dr. Sredstva al'ternativnoj terapii v lechenii bessonnitsy u pozhilyh patsientov // Farmatsija. 2014. № 8. S. 34−36.